¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£© U^ec g{  
dK5|tWJX  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© H\zV/1~Y  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© gCVgL]jj(  
1.Co-stimulators (or co-stimulating molecules) aCq ) hR  
2.NK-kB vS!%!-F  
3.Immunoglobulin superfamily E3):8>R;1  
4.antigen-presenting cell (APC) ]dx6E6A,  
5.death domain B.e3IM0  
6.CCR and CXCR 3X0"</G6  
7.Lectin (or mitogen) 4\cJ}p}LZ{  
8.Clusters of differentiation, CD) )} I>"n  
9.B7 family P6n9yJ$,cb  
10.Cytotoxic T lymphocyte, CTL) m0: IFE($  
11.IL-15 and IL-15 receptor (IL-15R) W[+=_B  
12.MHC restriction 1ZUmMa1(  
13.Affinity-chromatography *A2D}X3 s  
14.Cyctosprin A, CsA Gu3# y"a>  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) h!vq~g  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© j9V*f HK  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 aBBTcN%'  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ yX-h|Cr"  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢á¹¹¼°Æäʶ±?¿¹Ô­µÄÌØµã¡£ 7a,/DI2o  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© !| G 8b'  
ÃâÒßѧרҵ£º "kS(b4^  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 8P kw'.r  
Ïû»¯ÄÚ¿Æ£º jjT|@\-u  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ h#Z5vH  
ѪҺ²¡Ñ§×¨Òµ£º d0b`qk @4  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»